HWP
NBIX icon

Highline Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Highline Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55K Sell
27
-2
-7% -$297 ﹤0.01% 883
2026
Q1 		$3.82K Buy
+29
New +$3.85K ﹤0.01% 811

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Highline Wealth Partners's NBIX Position: Q2 2026 in Review

Highline Wealth Partners reduced its Neurocrine Biosciences (NBIX) stake by 6.9% in Q2 2026, selling an estimated $297 and leaving 27 shares worth $4.55K. The position accounts for ﹤0.01% of the portfolio, ranked #883.

Highline Wealth Partners first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Highline Wealth Partners held 27 shares of Neurocrine Biosciences worth $4.55K as of Q2 2026.
  • Highline Wealth Partners sold 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #883 holding.
  • Highline Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.